title: Response to letter from Garcia and colleagues on cholinesterase inhibitors and Alzheimer's disease outcomes.
authors.forename: Sophie
authors.initials: S
authors.lastname: Gillette-Guyonnet
authors.forename: Sandrine
authors.initials: S
authors.lastname: Andrieu
authors.forename: Fati
authors.initials: F
authors.lastname: Nourhashemi
authors.forename: Emma
authors.initials: E
authors.lastname: Reynish
authors.forename: Bruno
authors.initials: B
authors.lastname: Vellas
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D000077265:Donepezil; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil